+44 207 488 9947
In the case of Bolton Pharmaceutical Co 100 Limited -v- Swinghope Limited and Others [2005], the claimant was the new owner of a trade mark registered in respect of a pharmaceutical product which was commonly used to treat hypertension. It acquired the product from AZ, another pharmaceutical company, in September 2004, who had previously sold its trade mark rights to a Spanish company.
The claimant acquired the trade mark in the United Kingdom, and later realised that the product was being imported into the UK by certain third parties, including the defendant, and bearing its trade mark. They had not sought the claimant's consent and the claimant therefore commenced proceedings alleging that the defendants were illegally impinging on its market and as a result, they were causing the claimant 'harm'. The claimant applied for summary judgment.
The defendants argued that:
- The doctrine of exhaustion of rights applied, which provided that where a product had been put on the market in a member state by the trade mark owner or with his consent, there could be no question of infringement of that mark; and
- Estoppel applied, on the basis that the claimant had failed to assert his rights under the trade mark in the preceding five months.
The court held that the claimant's application for summary judgment would be allowed on the grounds that:
It followed therefore that any defence based on the doctrine of the exhaustion of rights had no real prospect of succeeding1.
The claimant was granted the relief sought.
This is the test that must be satisfied in order for an applicant to obtain a summary judgment.
If you require further information contact us.
Email: [email protected]
© RT COOPERS, 2005. This Briefing Note does not provide a comprehensive or complete statement of the law relating to the issues discussed nor does it constitute legal advice. It is intended only to highlight general issues. Specialist legal advice should always be sought in relation to particular circumstances.